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Region Infection Acquired  Recommended Drug and Adult Dose1  Recommended Drug and Pediatric Dose1 
Pediatric dose should NEVER exceed adult dose 
Uncomplicated malaria/  
   P. falciparum or 
   Species not identified 
 
If “species not 
identified” is 
subsequently diagnosed 
as P. vivax or P ovale: 
see P. vivax and P ovale 
(below) re. treatment 
with primaquine 
Chloroquine-resistant or unknown 
resistance2 
(All malarious regions except those specified 
as chloroquine-sensitive listed in the box 
below.) 
 
A. Atovaquone-proguanil (Malarone™)3 
       Adult tab = 250 mg atovaquone/ 100 mg proguanil 
       4 adult tabs po qd x 3 days 
 
 
A. Atovaquone-proguanil (Malarone™)3       
     Adult tab = 250 mg atovaquone/ 100 mg proguanil  
     Peds tab = 62.5 mg atovaquone/ 25 mg proguanil 
     5 - 8kg: 2 peds tabs po qd x 3 d      
     9-10kg: 3 peds tabs po qd x 3 d      
     11-20kg: 1adult tab po qd x 3 d 
     21-30kg: 2 adult tabs po qd x 3d 
     31-40kg: 3 adult tabs po qd x 3d 
     > 40 kg: 4 adult tabs po qd x 3d   
B. Artemether-lumefantrine (Coartem™)3 
     1 tablet = 20mg artemether and 120 mg lumefantrine 
     A 3-day treatment schedule with a total of 6 oral doses is recommended for both adult and pediatric patients based on 
    weight. The patient should receive the initial dose, followed by the second dose 8 hours later, then 1 dose po bid for the 
    following 2 days.    
    5 - <15 kg:   1 tablet per dose 
    15 - <25 kg: 2 tablets per dose 
    25 - <35 kg: 3 tablets per dose 
    ≥35 kg:        4 tablets per dose 
C. Quinine sulfate plus one of the following: Doxycycline, 
Tetracycline, or Clindamycin 
  Quinine sulfate:  542 mg base (=650 mg salt)4 po tid      
   x 3 or 7 days5  
   Doxycycline:  100 mg po bid x 7 days  
   Tetracycline:  250 mg po qid x 7 days   
   Clindamycin: 20 mg base/kg/day po divided tid x 7 days 
C. Quinine sulfate4 plus one of the following: 
Doxycycline6,   Tetracycline6 or Clindamycin 
   Quinine sulfate: 8.3 mg base/kg (=10 mg salt/kg) po    
   tid  x 3 or 7 days5    
   Doxycycline:  2.2 mg/kg po every 12 hours x 7 days  
   Tetracycline:  25 mg/kg/day po divided qid x 7 days  
   Clindamycin: 20 mg base/kg/day po divided tid x 7 days 
D. Mefloquine (Lariam™ and generics)7  
684 mg base (=750 mg salt) po as initial dose, followed by 456 
mg base (=500 mg salt) po given 6-12 hours after initial dose 
Total dose= 1,250 mg salt  
 
D. Mefloquine (Lariam™ and generics)7 
13.7 mg base/kg (=15 mg salt/kg) po as initial dose, 
followed by 9.1 mg base/kg (=10 mg salt/kg) po given  
6-12 hours after initial dose.  Total dose= 25 mg salt/kg89 
                                                 
1 If a person develops malaria despite taking chemoprophylaxis, that particular medicine should not be used as a part of their treatment regimen.  Use one of the other options instead.    
2  NOTE: There are 4 options (A, B, C, or D) available for treatment of uncomplicated malaria caused by chloroquine-resistant P. falciparum.  Options A, B, and C are equally recommended.  Because of a higher rate of 
severe neuropsychiatric reactions seen at treatment doses, we do not recommend option D (mefloquine) unless the other options cannot be used.  For option C, because there is more data on the efficacy of quinine in 
combination with doxycycline or tetracycline, these treatment combinations are generally preferred to quinine in combination with clindamycin.  
3 Take with with food or whole milk.  If patient vomits within 30 minutes of taking a dose, then they should repeat the dose.  
4 US manufactured quinine sulfate capsule is in a 324mg dosage; therefore 2 capsules should be sufficient for adult dosing. Pediatric dosing may be difficult due to unavailability of non-capsule forms of quinine.  
5 For infections acquired in Southeast Asia, quinine treatment should continue for 7 days.  For infections acquired elsewhere, quinine treatment should continue for 3 days. 
6 Doxycycline and tetracycline are not indicated for use in children less than 8 years old. For children less than 8 years old with chloroquine-resistant P. falciparum, atovaquone-proguanil and artemether-lumefantrine are 
recommended treatment options; mefloquine can be considered if no other options are available.  For children less than 8 years old with chloroquine-resistant P. vivax, mefloquine is the recommended treatment.  If it is not 
available or is not being tolerated and if the treatment benefits outweigh the risks, atovaquone-proguanil or artemether-lumefantrine should be used instead.   
7 Treatment with mefloquine is not recommended in persons who have acquired infections from Southeast Asia due to drug resistance.    
8When treating chloroquine-sensitive infections, chloroquine and hydroxychloroquine are recommended options.  However, regimens used to treat chloroquine-resistant infections may also be used if available, more 
convenient, or preferred.   
9Primaquine is used to eradicate any hypnozoites that may remain dormant in the liver, and thus prevent relapses, in P. vivax and P. ovale infections.  Because primaquine can cause hemolytic anemia in G6PD-deficient 
persons, G6PD screening must occur prior to starting treatment with primaquine. For persons with borderline G6PD deficiency or as an alternate to the above regimen, primaquine may be given 45 mg orally one time per 
week for 8 weeks; consultation with an expert in infectious disease and/or tropical medicine is advised if this alternative regimen is considered in G6PD-deficient persons.  Primaquine must not be used during pregnancy. 
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Uncomplicated malaria/  
   P. falciparum or 
   Species not identified 
Chloroquine-sensitive 
(Central America west of Panama Canal; 
Haiti; the Dominican Republic; and most of 
the Middle East) 
Chloroquine phosphate (Aralen™ and generics)8 
600 mg base (=1,000 mg salt) po immediately, followed by 300 
mg base (=500 mg salt) po at 6, 24, and 48 hours   
Total dose:  1,500 mg base (=2,500 mg salt)   OR 
Hydroxychloroquine (PlaquenilTM and generics) 
620 mg base (=800 mg salt) po immediately, followed by 310 
mg base (=400 mg salt) po at 6, 24, and 48 hours   
Total dose:  1,550 mg base (=2,000 mg salt) 
Chloroquine phosphate (Aralen™ and generics) 8 
10 mg base/kg po immediately, followed by 5 mg base/kg 
po at 6, 24, and 48 hours   
Total dose:  25 mg base/kg     OR 
Hydroxychloroquine (PlaquenilTM and generics) 
10 mg base/kg po immediately, followed by 5 mg base/kg 
po at 6, 24, and 48 hours   
Total dose:  25 mg base/kg 
Uncomplicated malaria/  
P. malariae or P. knowlesi 
All regions Chloroquine phosphate: 8 Treatment as above      OR 
Hydroxychloroquine: Treatment as above 
Chloroquine phosphate: 8 Treatment as above      OR 
Hydroxychloroquine: Treatment as above 
Uncomplicated malaria/  
   P. vivax or 
   P. ovale 
All regions 
Note: for suspected chloroquine-resistant P. 
vivax, see row below 
Chloroquine phosphate8 plus Primaquine phosphate9 
     Chloroquine phosphate:  Treatment as above  
     Primaquine phosphate:  30 mg base po qd x 14 days     OR 
Hydroxychloroquine plus Primaquine phosphate9 
     Hydroxychloroquine: Treatment as above 
     Primaquine phosphate:  30 mg base po qd x 14 days 
Chloroquine phosphate8 plus Primaquine phosphate9 
  Chloroquine phosphate:  Treatment as above  
  Primaquine: 0.5mg base/kg po qd x 14 days              OR  
Hydroxychloroquine plus Primaquine phosphate9 
  Hydroxychloroquine: Treatment as above 
  Primaquine phosphate: 0.5mg base/kg po qd x 14 days               
Uncomplicated malaria/  
   P. vivax  
 
Chloroquine-resistant10  







A. Quinine sulfate plus either Doxycycline or Tetracycline 
plus Primaquine phosphate9 
     Quinine sulfate:  Treatment as above 
     Doxycycline or Tetracycline:  Treatment as above  
     Primaquine phosphate:  Treatment as above   
A. Quinine sulfate plus either Doxycycline6 or 
Tetracycline6 plus Primaquine phosphate9 
     Quinine sulfate:  Treatment as above 
     Doxycycline or Tetracycline:  Treatment as above  
     Primaquine phosphate:  Treatment as above   
B. Atovaquone-proguanil plus Primaquine phosphate9 
      Atovaquone-proguanil:  Treatment as above 
      Primaquine phosphate:  Treatment as above   
B. Atovaquone-proguanil plus Primaquine phosphate9 
      Atovaquone-proguanil:  Treatment as above 
      Primaquine phosphate:  Treatment as above   
C. Mefloquine plus Primaquine phosphate9 
      Mefloquine:  Treatment as above 
      Primaquine phosphate:  Treatment as above   
C. Mefloquine plus Primaquine phosphate9 
      Mefloquine:  Treatment as above 
      Primaquine phosphate:  Treatment as above  
Uncomplicated malaria: 
alternatives for pregnant 
women11,12,13 
Chloroquine-sensitive 
(see uncomplicated malaria sections above for 
chloroquine-sensitive species  by region) 
Chloroquine phosphate: Treatment as above       OR 
Hydroxychloroquine: Treatment as above 
Not applicable 
Chloroquine-resistant 
(see sections above for regions with 
chloroquine resistant P. falciparum and        
P. vivax) 
Quinine sulfate plus Clindamycin 
    Quinine sulfate:  Treatment as above  
    Clindamycin:   Treatment as above  
                                                                                  OR 
Mefloquine:  Treatment as above 
Not applicable 
                                                 
10  NOTE: There are three options (A, B, or C) available for treatment of uncomplicated malaria caused by chloroquine-resistant P. vivax.  High treatment failure rates due to chloroquine-resistant P. vivax have been well documented 
in Papua New Guinea and Indonesia.  Rare case reports of chloroquine-resistant P. vivax have also been documented in Burma (Myanmar), India, and Central and South America.  Persons acquiring P. vivax infections outside of 
Papua New Guinea or Indonesia should be started on chloroquine.  If the patient does not respond, the treatment should be changed to a chloroquine-resistant P. vivax regimen and CDC should be notified (Malaria Hotline number 
listed above).  For treatment of chloroquine-resistant P. vivax infections, options A, B, and C are equally recommended.    
11 For pregnant women diagnosed with uncomplicated malaria caused by chloroquine-resistant P. falciparum or chloroquine-resistant P. vivax infection, treatment with doxycycline or tetracycline is generally not indicated.  
However, doxycycline or tetracycline may be used in combination with quinine (as recommended for non-pregnant adults) if other treatment options are not available or are not being tolerated, and the benefit is judged to 
outweigh the risks.   
12 Atovaquone-proguanil and artemether-lumefantrine are generally not recommended for use in pregnant women, particularly in the first trimester due to lack of sufficient safety data.  For pregnant women diagnosed with 
uncomplicated malaria caused by chloroquine-resistant P. falciparum infection, atovaquone-proguanil or artemether-lumefantrine may be used if other treatment options are not available or are not being tolerated, and if the 
potential benefit is judged to outweigh the potential risks.   
13 For P. vivax and P. ovale infections, primaquine phosphate for radical treatment of hypnozoites should not be given during pregnancy.  Pregnant patients with P. vivax and P. ovale infections should be maintained on 
chloroquine prophylaxis for the duration of their pregnancy.  The chemoprophylactic dose of chloroquine phosphate is 300 mg base (=500 mg salt) orally once per week.  After delivery, pregnant patients who do not have 
G6PD deficiency should be treated with primaquine. 
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14Severe malaria 14,15, 16 
    
 
 
All regions Quinidine gluconate14 plus one of the following: 
Doxycycline, Tetracycline, or Clindamycin 
    Quinidine gluconate:  6.25 mg base/kg (=10 mg salt/kg) 
loading dose IV over 1-2 hrs, then 0.0125 mg base/kg/min 
(=0.02 mg salt/kg/min) continuous infusion for at least 24 
hours.  An alternative regimen is 15 mg base/kg (=24 mg 
salt/kg) loading dose IV infused over 4 hours, followed by 7.5 
mg base/kg (=12 mg salt/kg) infused over 4 hours every 8 
hours, starting 8 hours after the loading dose (see package 
insert). Once parasite density <1% and patient can take oral 
medication, complete treatment with oral quinine, dose as 
above.  Quinidine/quinine course = 7 days in Southeast Asia; = 
3 days in Africa or South America. 
    Doxycycline:  Treatment as above. If patient not able to take 
oral medication, give 100 mg IV every 12 hours and then switch 
to oral doxycycline (as above) as soon as patient can take oral 
medication.  For IV use, avoid rapid administration. Treatment 
course = 7 days. 
    Tetracycline:  Treatment as above 
    Clindamycin:  Treatment as above.  If patient not able to 
take oral medication, give 10 mg base/kg loading dose IV 
followed by 5 mg base/kg IV every 8 hours. Switch to oral 
clindamycin (oral dose as above) as soon as patient can take 
oral medication.  For IV use, avoid rapid administration.  
Treatment course = 7 days. 
 
Investigational new drug (contact CDC for information): 
Artesunate followed by one of the following: Atovaquone-
proguanil (Malarone™), Doxycycline (Clindamycin in 
pregnant women), or Mefloquine 
Quinidine gluconate14 plus one of the following: 
Doxycycline4, Tetracycline4, or Clindamycin   
    Quinidine gluconate:  Same mg/kg dosing and 
recommendations as for adults. 
     Doxycycline:  Treatment as above. If patient not able to 
take oral medication, may give IV.  For children <45 kg, 
give 
2.2 mg/kg IV every 12 hours and then switch to oral 
doxycycline (dose as above) as soon as patient can take 
oral medication.  For children >45 kg, use same dosing as 
for adults.  For IV use, avoid rapid administration. 
Treatment course = 7 days. 
      Tetracycline:  Treatment as above 
      Clindamycin:  Treatment as above.  If patient not able 
to take oral medication, give 10 mg base/kg loading dose 
IV followed by 5 mg base/kg IV every 8 hours. Switch to 
oral clindamycin (oral dose as above) as soon as patient 
can take oral medication.  For IV use, avoid rapid 
administration.  Treatment course = 7 days. 
 
Investigational new drug (contact CDC for information): 
Artesunate followed by one of the following: 




                                                 
14 Persons with a positive blood smear OR history of recent possible exposure and no other recognized pathology who have one or more of the following clinical criteria (impaired consciousness/coma, severe normocytic 
anemia, renal failure, pulmonary edema, acute respiratory distress syndrome, circulatory shock, disseminated intravascular coagulation, spontaneous bleeding, acidosis, hemoglobinuria, jaundice, repeated generalized 
convulsions, and/or parasitemia of > 5%) are considered to have manifestations of more severe disease. Severe malaria is most often caused by P. falciparum. 
15Patients diagnosed with severe malaria should be treated aggressively with parenteral antimalarial therapy.  Treatment with IV quinidine should be initiated as soon as possible after the diagnosis has been made.  Patients 
with severe malaria should be given an intravenous loading dose of quinidine unless they have received more than 40 mg/kg of quinine in the preceding 48 hours or if they have received mefloquine within the preceding 12 
hours.  Consultation with a cardiologist and a physician with experience treating malaria is advised when treating malaria patients with quinidine.  During administration of quinidine, blood pressure monitoring (for 
hypotension) and cardiac monitoring (for widening of the QRS complex and/or lengthening of the QTc interval) should be monitored continuously and blood glucose (for hypoglycemia) should be monitored periodically.  
Cardiac complications, if severe, may warrant temporary discontinuation of the drug or slowing of the intravenous infusion. 
16 Pregnant women diagnosed with severe malaria should be treated aggressively with parenteral antimalarial therapy. 
